Mantle Cell Lymphoma
Return to Cancer Menu
Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes in the lymph nodes. It often progresses quickly and requires timely diagnosis and treatment. Here's a breakdown of its key features:
Characteristics:
- Origin: Starts in the mantle zone, a part of the lymph node rich in B-lymphocytes.
- Aggressiveness: Grows and spreads faster than other types of NHL.
- Incidence: Accounts for about 6% of all NHL cases in the United States.
- Risk factors: Age (mostly above 60), male gender, previous history of other lymphomas.
Symptoms:
- Enlarged lymph nodes: Usually painless, but noticeable in the neck, groin, or underarms.
- Fatigue: A persistent feeling of tiredness and lack of energy.
- Night sweats: Drenching sweats during sleep.
- Unexplained weight loss: Losing weight without trying.
- Fever: May be recurrent or persistent.
- Other symptoms: Less common symptoms include bone pain, shortness of breath, and abdominal pain.
Diagnosis:
- Blood tests: Complete blood count and blood smear check for abnormal white blood cells.
- Bone marrow biopsy: Examines bone marrow for lymphoma cells.
- Lymph node biopsy: Tissue sample from an enlarged lymph node confirms the diagnosis and specific type of MCL.
- Imaging tests: CT scans or PET scans show the extent of lymph node involvement and potential spread to other organs.
Treatment:
- Depends on stage, overall health, and other factors:
- Early stages: Chemotherapy with or without radiation therapy.
- Advanced stages: More intensive chemotherapy with stem cell transplantation considered.
- Targeted therapies: Newer drugs like bendamustine and ibrutinib show promise in treating MCL.
- Stem cell transplantation: High-dose chemotherapy followed by stem cell infusion restores healthy blood cell production.
Prognosis:
- Varied: Depends on stage, individual risk factors, and response to treatment.
- Five-year survival rate: Ranges from 50% to 70% depending on the stage and other factors.
- Early diagnosis and treatment: Crucial for better outcomes.
- Regular monitoring: Essential to detect recurrences and potential complications.
Articles/Studies
Borrelia infection and risk of non-Hodgkin lymphoma Reports of the presence of Borrelia burgdorferi DNA in malignant lymphomas have raised the hypothesis that infection with B burgdorferi may be causally related to non-Hodgkin lymphoma (NHL) development. We conducted a Danish-Swedish case-control study including 3055 NHL patients and 3187 population controls. History of tick bite or Borrelia infection was ascertained through structured telephone interviews and through enzyme-linked immunosorbent assay serum analyses for antibodies against B burgdorferi in a subset of 1579 patients and 1358 controls. Statistical associations with risk of NHL, including histologic subtypes, were assessed by logistic regression. Overall risk of NHL was not associated with self-reported history of tick bite (odds ratio [OR] = 1.0; 95% confidence interval: 0.9-1.1), Borrelia infection (OR = 1.3 [0.96-1.8]) or the presence of anti-Borrelia antibodies (OR = 1.3 [0.9-2.0]). However, in analyses of NHL subtypes, self-reported history of B burgdorferi infection (OR = 2.5 [1.2-5.1]) and seropositivity for anti-Borrelia antibodies (OR = 3.6 [1.8-7.4]) were both associated with risk of mantle cell lymphoma. Notably, this specific association was also observed in persons who did not recall Borrelia infection yet tested positive for anti-Borrelia antibodies (OR = 4.2 [2.0-8.9]). Our observations suggest a previously unreported association between B burgdorferi infection and risk of mantle cell lymphoma.
Complementary Therapies for Mantle Cell Lymphoma
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.